European Psychiatry - Volume 33 - March 2016

363 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S359
patients attended only the first visit. Four (36.4) achieved complete
abstinence, 3 (27.27) met maintenance phase. One (9.1) reduced
consumption in half. Patients gained average 0.5 kg (2.47).
Conclusions The results are similar to those reported in other
series. Modest dropout rate. No pharmacological treatment was
used due to high coexistence of comorbidities, the only patient
who used varenicline suffered insomnia. Average age and media
packages were superior to other series.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV30
Smoking reduction/cessation and
psychiatric patients: What about
weight control?
I. Ganhao ∗, M. Trigo , A. Paixao , J. Cardoso
1 Qta do Anjo, Portugal
2 Centro Hospitalar Psiquiatrico de Lisboa, Smoking
Reduction/Cessation Program, Lisbon, Portugal
∗ Corresponding author.
Introduction Smoking cessation has long been associated with
weight gain and is one of the many reasons that smokers invoke
for not giving up smoking. Many psychiatric medications are also
associated with increased weight gain and metabolic syndrome.
Unhealthy lifestyles reflect symptoms of illness with poor coping
strategies and financial and social difficulties.
There are many reasons why smoking cessation may be viewed as
much more difficult for psychiatric patients and weight gain is one
of them.
Objective To study how patients’ weight evolves during smoking
reduction and cessation in a smoking reduction/cessation program
in a psychiatric hospital.
Aims To demystify weight gain as a significant problem in smok-
ing reduction and cessation in this patient population.
Methods Every patient entering the smoking reduction/cessation
program is evaluated initially with regard to weight and BMI.
Patients’ weights are evaluated during the duration of the program
for each patient as is smoking status.
Results We are still collecting data at this time.
Conclusions There are three groups of patient according toweight
changes during the program: those who gain weight, those who
maintain the same weight (± 1 kg) and those who lose weight.
Most patients who gain weight end up recuperating their initial
weight or are able to lose weight later.
Some patients had weight control issues and their fear of gaining
weight led them to overcompensate leading to weight loss.
We have included interventions on healthy lifestyles that have
aided patients in controlling their weight.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV31
Personality dimensions and drug of
choice: A descriptive study using
Cloninger’s temperament and
character inventory revised
G. Hurtado ∗, G. Mateu , R. Martinez , A. Farre , J. Marti ,
R. Sanchez , L. Diaz , M. Campillo
1 Parc de Salut Mar, Institut de Neuropsiquiatria i AddicionsCentre
Emili Mira, Santa Coloma Gramenet, Spain
2 Parc de Salut Mar, Institut de Neuropsiquiatria i Addicions Centre
Emili Mira, Barcelona, Spain
∗ Corresponding author.
Personality dimensions related with drug use are novelty seeking,
impulsivity and harm avoidance. Studies predicting drug of choice
over personality variables are controversial.
Objective To describe personality profile of drug users in relation
to substance of choice.
Aims To know personality dimension differences according to
drug used.
Methods Cloninger’s TCI-R was administered to 218 patients in a
dual diagnosis unit.
SPSS was applied.
Results Of the patients, 33.94%had personality disorder. Principal
substances used were alcohol, cocaine and cannabis.
Most of drug users had normal scores in each dimension. No high
scores were found in reward dependence, self-directedness and
cooperativeness with any drug.
High scores were observed for novelty seeking in 42.9% of timu-
lants users; for arm avoidance in a quarter of cocaine, alcohol and
methadone users and for persistence in 18.2% of hypnotics users.
Low scores were observed for reward dependence in 45% of hero-
ine and hypnotics users; for persistence in 50% of methadone and
32% of cocaine users; for self-directedness in most of types of drug
users and for cooperativeness in up to 50% in heroine, hypnotics,
stimulants and cocaine users.
Statistical significant differences were observed for cocaine use and
high novelty seeking and low cooperation; for non cannabis use
and high harm avoidance; for non anfetamine use and low scores
in reward dependence; for opiate use and low self-directedness.
Conclusions Most of patients had normal scores in the different
dimensions.
Presence of comorbid personality disorder led us to consider the
results with caution.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV32
Depression, anxiety and panic
disorders in chronic obstructive
pulmonary disease: Correlations with
disease severity and quality of life
R. Gherghesanu ∗, L. Trofor (PhD student) ,
I.O. Pascal (PhD student) , R. Chirita , A. Frunza
1 Iasi, Romania
2 “Gr.T.Popa” University of Medicine and Pharmacy- Iasi- Romania,
psychiatry 1, Iasi, Romania
3 University of Medicine and Pharmacy “Gr.T.Popa” Iasi, psychiatry 1,
Iasi, Romania
4 Faculty of Bioengineering U.M.F “Gr.T.Popa” Iasi, bioengineery 1,
Iasi, Romania
∗ Corresponding author.
Introduction Depression, anxiety and panic disorders are often
encountered in chronic respiratory disorders, like chronic obstruc-
tive pulmonary disease (COPD), especially in severe disease stages
with impaired quality of life.
Aim To assess anxiety, depression and panic disorders among
patients diagnosed with COPD and to correlate them with respi-
ratory disease severity and quality of life.
Material and method We investigated the profile of anxiety,
depression and panic attacks in relation to patients’ medical his-
tory, demographic data, smoking status, COPD staging and disease
severity (estimated by CAT quality of life questionnaire, GOLD
guideline staging).
Results A total of 60 COPD patients were enrolled. Smoking
profile showedmore intensive smoking inmen (35.81mean packs-
years versus 24.38 in women). The COPD high-risk group type D
was predominant, with severe dyspnea, decreased lung function,
frequent exacerbations and low quality of life (mean CAT score: